|Videos|August 12, 2011

Prescription Acetaminophen-Opioid Combinations: Making Pain Medicines Safer

Sandy Kweder, deputy director of the FDA's Office of New Drugs, talks about the implications of the FDA's announcement earlier this year that all prescription combinations of opioids and acetaminophen are required to contain no more than 325 mg of acetaminophen per tablet.

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Prescription Acetaminophen-Opioid Combinations: Making Pain Medicines Safer

Related Content

Tirzepatide Cuts MACE Risk in Diabetes With Heart Disease

The Side Door We Could Close: A Pharmacy Perspective on Menopause, Access, and the Leadership Pipeline

Q&A: Prepare for FDA Inspection on Compounded GLP-1s

Study Reveals a Widening Gap Between Buprenorphine Prescribing and Dispensing

Why Open Communication Across Specialties Is Critical to Complex SM Care

Latest CME

Redefining Complement-Mediated Kidney Disease: The Latest in Diagnosis and Treatment

Navigating the Legal Landscape of Telehealth: Updates and Implications for Pharmacists and Technicians (Pharmacy Technician Credit)

Clinical Presentation of Hyperglycemia with PI3K and AKT Inhibitors

Protecting Against Meningococcal Disease: Updates on Vaccines, Guidelines, and Pharmacist Best Practices

Targeting the Root of Autoimmunity in Generalized Myasthenia Gravis: Pharmacist Strategies for Integrating FcRn Therapies Into Specialty Practice

IL-23 Inhibitors in Psoriasis: Optimizing Access and Patient Outcomes Across Integrated Systems

Utilizing VMAT-2 Inhibitors for the Management of Tardive Dyskinesia: The Role of Long-Term Care Pharmacists

From Guidelines to Action: Implementing Pneumococcal Vaccine ACIP Recommendations in Long-Term Care Settings

Influenza Immunization in Older Adults: Enhanced Vaccines and Best Practices for Long-Term Care Pharmacists

Multidisciplinary Insights and Strategies for Patients Treated With PI3K and AKT Inhibitors to Prevent Hyperglycemia

Navigating Advanced Prostate Cancer Treatment: Optimizing Novel Therapeutic Strategies for Managed Care Pharmacists

Innovations in Retinal Therapies: A Managed Care Perspective on Anti-VEGF Advancements

Multidisciplinary Insights to Enhance Biomarker Testing Practices in Non-Small Cell Lung Cancer

Minimizing Injection Burden: Anti-VEGF Innovation for Retinal Disease Management

Transforming Gout Care: Navigating Barriers and Therapeutic Advances in Disease Management

Beyond the Nasal Passage: Managing Chronic Rhinosinusitis With Nasal Polyps With Biologics and Pharmacist-Led Approaches

New Therapeutic Targets in the Treatment of Generalized Myasthenia Gravis: Understanding Disease Pathways and Pharmacist-Led Strategies for Optimized Care

Payment for Pharmacist Services: 2025 Update

From Treatment to Prevention: Navigating the Expanding Hereditary Angioedema Treatment Landscape

Advancing Pharmacist Expertise in R/R FL: Navigating Novel Therapies and Optimizing Patient Outcomes

Paroxysmal Nocturnal Hemoglobinuria: Managed Care Strategies to Mitigate Burden and Enhance Outcomes

Optimizing Outcomes in Myasthenia Gravis: Therapeutic Advances and Value-Based Care Models

Navigating Novel Therapies in Steroid-Refractory cGVHD: Practical Strategies for Community-Based Oncology Pharmacists

Clinical Panel Debate: CAR T-Cell Therapy vs Bispecific Antibodies

The Pharmacist's Role in Palliative and End of Life Symptom Management

From Testing to Treatment: Empowering Pharmacists to Overcome Barriers and Optimize Biomarker-Driven Care

Redefining Care in Polycythemia Vera and Essential Thrombocythemia: Emerging Evidence, Evolving Strategies, and the Pharmacist’s Role

Advancing the Management of Hidradenitis Suppurativa: Emerging Therapies and Managed Care Strategies Across Patient Populations

NEIAP Conference 2026

Innovations in Narcolepsy Treatment: Emerging Targets and Implications for Managed Care

Evolving Treatment Options in Plaque Psoriasis: Implications of Emerging TYK2 Inhibitors for Managed Care

New Treatments in Systemic Lupus Erythematosus to Advance Care: A Managed Care Focus on Nephritis

Looking at Patient-Centered Care in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema Through a Value-Based Lens

PBMI 2026

Lymphoma Day of Education 2026

Shingles Vaccination: Opportunities for Pharmacist Interventions to Provide Patient Education

Reducing Transfusion Burden in Myeloid Disorders: Novel Therapeutic Strategies and Pharmacist Interventions

Infectious Disease Day of Education 2026

Infectious Disease Day of Education 2026

Panel Discussion: Integrating Novel Combinations and Earlier Line Use in Diffuse Large B-Cell Lymphoma

Optimizing Patient Outcomes in R/R DLBCL: Bridging Knowledge Gaps for Oncology Pharmacists in the Era of Novel Immunotherapies

From Molecules to Medicine: Pharmacologic Principles of Innovative Non-Hodgkin Lymphoma Therapies

The Pharmacist's Role in Palliative and End of Life Symptom Management (Pharmacy Technician Credit)

Precision Matters: Foundations of Biomarker-Driven Care in Non-Small Cell Lung Cancer

Navigating the Legal Landscape of Telehealth: Updates and Implications for Pharmacists and Technicians

Advancing Treatment Strategies in Extensive-Stage Small Cell Lung Cancer: Enhancing Pharmacist Competence in Therapy Selection, Administration, and Adverse Event Management

Pharmacists at the Forefront: Enhancing Targeted Therapy Implementation and Patient Outcomes in Advanced Gastric Cancer

Bridging Clinical and Access Gaps in Phenylketonuria: A Managed Care Perspective

Sugar, We’re Going Down: Navigating Glycemic Control in the Era of PI3K/AKT Inhibition for Breast Cancer

From Payload to Patient: Managing Toxicities of Antibody-Drug Conjugates Directed at HER2 and TROP2

Exploring Immunotherapy Strategies in Endometrial Cancer

Best Practice Approaches for Understanding Chronic Obstructive Pulmonary Disease and Precision Medicine Treatment

Advancing the Idiopathic Pulmonary Fibrosis Treatment Landscape: What’s Next in Care

Collaborative Practice Agreement Implementation and Adherence: A Practical Roadmap for Oncology Pharmacists

HER2-Positive Metastatic Breast Cancer: A Managed Care Perspective on Emerging Therapies and Clinical Data

Biomarker Testing in Practice: Navigating Modalities and Multidisciplinary Decision-Making

Enhancing The Role of Oncology Pharmacists in Multidisciplinary Myeloproliferative Neoplasm Care

Advancing Patient Safety: Strategies to Address Safety Risks and Adherence Barriers to Optimize Outcomes for Patients on Injectable Therapies

An American Journal of Managed Care Forum: Bridging Evidence and Access in Advanced Small Cell Lung Cancer

The Educated Pharmacist: Overcoming Clinical Inertia—An Interactive Case Workshop for Optimizing Insulin Use

Advancing Chronic Kidney Disease Detection and Cardiovascular Risk Reduction in Complex Patients

Navigating the Complexities of Personalized Prostate Cancer Care: Insights for Oncology Managed Care

Two Targets, One Mission: Optimizing Bispecific Antibody Use in Non-Hodgkin Lymphoma

Artificial Intelligence in Pharmacy Practice: Validated Tools, Real-World Applications, and Emerging Innovations (Pharmacy Technician Credit)

Artificial Intelligence in Pharmacy Practice: Validated Tools, Real-World Applications, and Emerging Innovations

Continuing the Conversation: Pharmacist Interventions to Optimize T2D Care and Break Through Clinical Inertia

Hat Trick for Hypertension: Strategies to Improve Outcomes With Single-Pill Combinations

New Drug Approvals for 2025 (Pharmacy Technician Credit)

Advancing HER2-Driven Cancer Care, Biomarker Testing, and Pharmacist Innovation

Stop and Smell the ROSis: Translating Molecular Results Into Actionable Pharmacy Practice in ROS1-Rearranged NSCLC

Innovations in Hidradenitis Suppurativa Treatment: Navigating the Evolving Landscape

Lymphoma Day of Education 2026